NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INM
Post# of 33
(Total Views: 292)
Posted On: 07/03/2019 3:42:18 PM
NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Co-Founder and CEO Showcases XPro1595 at Maxim Group’s Conference on Alzheimer’s Disease
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its co-founder and CEO, R.J. Tesi, M.D., presented at the Maxim Group’s conference on Alzheimer’s disease on June 26 in New York. According to the update, Tesi’s presentation addressed how INmune Bio’s XPro1595 drug candidate targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease. “I was delighted to showcase INmune Bio’s development program with XPro1595 in Alzheimer’s disease,” Tesi said in the news release. “We believe that our Phase I clinical trial supported by the Alzheimer’s Association Part-the-Cloud Award is a positive step in exploring if reversing microglial activation and neuroinflammation will have an impact on this devastating disease.” INmune Bio intends to begin enrolling patients into Xpro1595’s Phase I clinical trial in the coming weeks.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its co-founder and CEO, R.J. Tesi, M.D., presented at the Maxim Group’s conference on Alzheimer’s disease on June 26 in New York. According to the update, Tesi’s presentation addressed how INmune Bio’s XPro1595 drug candidate targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease. “I was delighted to showcase INmune Bio’s development program with XPro1595 in Alzheimer’s disease,” Tesi said in the news release. “We believe that our Phase I clinical trial supported by the Alzheimer’s Association Part-the-Cloud Award is a positive step in exploring if reversing microglial activation and neuroinflammation will have an impact on this devastating disease.” INmune Bio intends to begin enrolling patients into Xpro1595’s Phase I clinical trial in the coming weeks.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)